Perseus Proteomics (TSE:4882) Change In Receivables : 円0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics Change In Receivables?

Perseus Proteomics's change in receivables for the quarter that ended in Dec. 2023 was 円0.00 Mil. It means Perseus Proteomics's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Perseus Proteomics's change in receivables for the fiscal year that ended in Mar. 2023 was 円0.30 Mil. It means Perseus Proteomics's Accounts Receivable declined by 円0.30 Mil from Mar. 2022 to Mar. 2023 .

Perseus Proteomics's Accounts Receivable for the quarter that ended in Dec. 2023 was 円13.63 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Perseus Proteomics's Days Sales Outstanding for the three months ended in Dec. 2023 was 59.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Perseus Proteomics's liquidation value for the three months ended in Dec. 2023 was 円1,434.19 Mil.

Perseus Proteomics Change In Receivables Historical Data

The historical data trend for Perseus Proteomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics Change In Receivables Chart

Perseus Proteomics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-157.24

187.24

1.08

-1.36

0.30

Perseus Proteomics Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial												-	-	-	-	-

Perseus Proteomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

Perseus Proteomics (TSE:4882) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Perseus Proteomics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	13.627	/	20.748	*	91
=	59.93

2. In Ben Graham's calculation of liquidation value, Perseus Proteomics's accounts receivable are only considered to be worth 75% of book value:

Perseus Proteomics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1663.576	-	241.103	+	0.75 * 13.627	+	0.5 * 2.992
=	1,434.19

Perseus Proteomics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Perseus Proteomics (TSE:4882) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041

Website

https://www.ppmx.com

Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines